Perspective Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.45 | -$0.10 | -$0.28 |
Q2 2024 | 1 | -$0.33 | -$0.08 | -$0.21 |
Q3 2024 | 1 | -$0.34 | -$0.08 | -$0.21 |
Q4 2024 | 4 | -$0.30 | -$0.19 | -$0.25 |
Q1 2025 | 1 | -$0.36 | -$0.25 | -$0.31 |
Q2 2025 | 1 | -$0.54 | -$0.12 | -$0.33 |
Q3 2025 | 1 | -$0.58 | -$0.13 | -$0.36 |
Q4 2025 | 1 | -$0.62 | -$0.14 | -$0.38 |
Q1 2026 | 1 | -$0.48 | -$0.11 | -$0.30 |
Q2 2026 | 1 | -$0.48 | -$0.11 | -$0.30 |
Q3 2026 | 1 | -$0.50 | -$0.11 | -$0.31 |
Q4 2026 | 1 | -$0.52 | -$0.12 | -$0.32 |
Perspective Therapeutics, Inc. Earnings Date And Information
Perspective Therapeutics, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.17 earnings per share for the quarter, topping analysts' consensus estimates of $-0.21 by $0.04. The company had revenue of 1.91 M for the quarter and had revenue of 7.10 M for the year. Perspective Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.1 diluted earnings per share) and currently has a price-to-earnings ratio of -90.98. Perspective Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based on prior year's report dates.
Perspective Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
09/29/2023 | Q1 2023 | -$0.04 | $2.60 M | $1.91 M | ||
06/30/2023 | Q4 2022 | -$0.04 | $2.06 M | $1.50 M | ||
03/31/2023 | Q3 2022 | -$0.00 | $1.83 M | |||
12/30/2022 | Q2 2022 | -$0.02 | $1.84 M | |||
11/14/2022 | Q1 2022 | -$0.01 | -$0.03 | -0.02 | $2.95 M | $1.72 M |
12/30/2022 | Q4 2021 | -$0.01 | $2.49 M | $2.51 M | ||
11/14/2022 | Q3 2021 | -$0.01 | -$0.01 | 0 | $2.91 M | |
09/28/2022 | Q2 2021 | -$0.01 | -$0.01 | -0 | $2.82 M | |
05/12/2022 | Q1 2021 | -$0.02 | $2.40 M | $2.56 M | ||
02/09/2022 | Q4 2020 | -$0.01 | $2.85 M | $2.71 M | ||
11/10/2021 | Q3 2020 | -$0.01 | -$0.01 | 0 | $2.60 M | |
09/27/2021 | Q2 2020 | -$0.01 | $2.36 M | |||
05/13/2021 | Q1 2020 | -$0.01 | $2.30 M | $2.38 M | ||
02/09/2021 | Q4 2019 | -$0.01 | -$0.02 | -0.01 | $2.12 M | $2.28 M |
11/13/2020 | Q3 2019 | -$0.01 | $2.88 M | |||
09/24/2020 | Q2 2019 | -$0.01 | $2.21 M | |||
05/13/2020 | Q1 2019 | -$0.01 | $2.32 M | |||
02/12/2020 | Q4 2018 | -$0.02 | $1.92 M | |||
11/13/2019 | Q3 2018 | -$0.02 | $1.92 M | |||
09/27/2019 | Q2 2018 | -$0.02 | $1.90 M |
Perspective Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Perspective Therapeutics, Inc.'s earnings date?
Perspective Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates.
-
Did Perspective Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Perspective Therapeutics, Inc. (:CATX) reported $-0.17 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.21 by $0.04.
-
How can I listen to Perspective Therapeutics, Inc.'s earnings conference call?
The conference call for Perspective Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Perspective Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Perspective Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Perspective Therapeutics, Inc. generate each year?
Perspective Therapeutics, Inc. (:CATX) has a recorded annual revenue of $7.10 M.
-
How much profit does Perspective Therapeutics, Inc. generate each year?
Perspective Therapeutics, Inc. (:CATX) has a recorded net income of $7.10 M. Perspective Therapeutics, Inc. has generated $-0.1 earnings per share over the last four quarters.
-
What is Perspective Therapeutics, Inc.'s price-to-earnings ratio?
Perspective Therapeutics, Inc. (:CATX) has a price-to-earnings ratio of -90.98 and price/earnings-to-growth ratio is 8.26.